Hormone therapy after endometrial cancer

A O Mueck and H Seeger

Section of Endocrinology and Menopause, Women’s University Hospital, Tuebingen, Germany

Abstract

Endometrial carcinoma is listed under the absolute contraindications to hormone therapy (HT). According to current opinion, HT after stage I or II is still considered an option, and continuous combined oestrogen/progestogen replacement therapy (CEPT) would be recommended. However, up to now, only observational studies have been put forward. Although none of these studies have established an increased rate of recurrence or mortality, alternatives such as phytopreparations and tibolone, or particular psychotherapeutic drugs, such as venlafaxine, should be considered for the relief of climacteric complaints. Progestogen-only therapy (PT) particularly has been considered. However, the currently discussed possible progestogen effects regarding an increased risk of breast cancer have to be taken into account. Indeed, the wider discussion about the gestagen effects regarding the risk of breast cancer is to be considered. Generally, after hysterectomy, at least for patients with cardiovascular risk factors, the preference today is to use low-dose oestrogen therapy (patches or gels) instead of CCEPT, and this is also now recommended for patients after endometrial cancer. This is to be noted because of the risk factors for endometrial carcinoma, such as hypertension, obesity, polycystic ovary syndrome (PCO) and diabetes mellitus. However, each form of HT should be only exceptionally recommended, and the patients must be informed about the risks that exist and the use of alternatives.

Introduction

The most common age for diagnosis of endometrial cancer (ECa) is 62–70 years of age (mean 67 years); however, 20–25% of these neoplasias appear pre-menopausally (Arbeitsgemeinschaft Krebsregister 2002). This early appearance of the disorder means obligatory operative therapy, with hysterectomy and bilateral salpingo-oophorectomy resulting in an iatrogenic, surgically induced menopause. The abrupt loss of oestrogen gives rise to corresponding deficiency symptoms, especially hot flushes, sleep disorders and depressive mood, greatly reducing quality of life. Consequently, the possibility of oestrogen replacement therapy after ECa must be considered. However, in addition to this, older women may also suffer from the consequences of oestrogen deficiency, with urogenital complaints and osteoporosis, so the question of oestrogen replacement also applies to them.

Present strategies — to be changed?

Hormone therapy (HT) can be administered by oestrogen-only therapy (ET) or oestrogen progestogen therapy (EPT) — the latter in the form of combined sequential EPT (CSEPT) or combined continuous EPT (CECEPT) (terminology according to Sturdee 2003). In the data sheets (summary of product characteristics) for such HT preparations, ECa is listed as a contraindication to therapy for ET alone, as well as for EPT, and also when the diagnosis was made many years before and the treatment therapy was obviously successful. Nevertheless, for 25 years, more patients are being treated with HT (preferably CCEPT) after therapy for ECa, mostly limited to FIGO stage 1, also more rarely to stage 2. Since up to 80% of all ECa are found to be stage 1 at the time of diagnosis (Arbeitsgemeinschaft Krebsregister 2002), many women may have the option of HT.

In the following discussion, it shall be pointed out how far HT (ET or EPT) after ECa has been investigated in studies and how the risks of HT are currently estimated, that is, after premature stopping of the Women’s Health Initiative study (evidence level I). In our opinion, new findings clearly show that the current recommendations of using HT after ECa preferably as EPT regimens should be thought about respectively and differentiated. Since the 1980s, ECa has not been listed under absolute
contraindications in the relevant consensus statements (German Society of Endocrinology 1988, 1996, American College of Obstetricians and Gynecologists 1993, 2001, Birkhäuser et al. 2003), although it is clearly stated that in the absence of prospective, randomised studies the effect of HT on the recurrence of ECa remains unknown. This assessment has obviously not been altered up to now (Creasman 1999), in contrast to new recommendations about HT after breast cancer (e.g. Chlebowski & McTiernan 1999, Natrajan et al. 1999, Emons 2002, Marsden 2002, Pritchard et al. 2002, Mueck & Wallwiener 2003).

Yet, for example, the negative gestagen effects, possibly on the breast, proved to deteriorate metabolism and the vessels, are to be taken into great consideration. This can bring into question the usual preference for combined hormone treatment (EPT instead of ET) after ECa. Possible alternatives, such as particular psychotherapeutic drugs or phytotherapy, tibolone and raloxifene, must also be discussed in this context, with assessment of use and risks, certainly always under the aspect that the most efficacious and sole causal treatment of menopausal complaints is represented by oestrogen.

**Oestrogen dependency-ECa type I**

In the developed world, ECa is the most frequent cancer of the female genital tract. In the USA, it was projected that 39 300 new cases would occur in 2002 and about 6600 women would die from the disease (American Cancer Society 2002). In Germany, the incidence per year is estimated to be about 10 000 cases, and ECa is the fourth most frequent malignancy in women after breast, colon, and rectal carcinoma (Arbeitsgemeinschaft Krebsregister 2002). Regarding oestrogen dependency, the ECa type I can be distinguished; it is associated with hyperoestrogenicity or oestrogen dominance (the risk factors are adipositas, anovulation, early menarche and late menopause) and is often preceded by hyperplastic endometrial changes. At the molecular level, mutation of the ras oncogene, depletion of the expression of tumour suppressor genes and disturbances in the function of DNA repair genes play a central role (Emons & Schulz 1998, Oehler et al. 2003). In contrast, ECa type II is not associated with hyperoestrogenicity and typically develops from the atrophic endometrium of post-menopausal women. Here mutation of the p53 gene seems to be important. Presumably, sex steroids are not crucial for the genesis of type II.

Recently, endometrial low-grade stromal sarcomas were found to be sensitive to oestrogens. Notably, over 50% were observed to be pre-menopausal, and the relapse rate, after bilateral ovariectomy and subsequent high-dose gestagen therapy, was greatly reduced. Accordingly, based on these studies (evidence level II-3), tumours of this primary type are considered a contraindication to HT (Römer & Mueck 2002).

Oestrogens work as typical tumour promoters in the formation of type 1 carcinoma. Through mitogenic activity, they increase the probability of endometrial hyperplasia, with possible progressive transformation to (mostly well-differentiated) carcinoma. Further mutations (in the p53-gene, loss of the expression of oestrogen and progesterone receptors, among other things) favour the transformation to more aggressive malignant, undifferentiated carcinoma with correspondingly worse prognosis (Oehler et al. 2003). It has recently been recognised that particular oestrogen metabolites are significant in the genesis of hormone-dependent tumours (Liehr 2000, Emons et al. 2003). In this context, we could demonstrate (studies of evidence levels I and II-1) that the kind and quantity of the metabolites can differ depending on the administered HT, and that they can also be strongly influenced by exogenous factors, such as smoking (Mueck et al. 2002, Mueck & Seeger 2003).

**ECa during HT — primary risk**

It is well recognised that the primary risk of ECa can be reduced through a combination of oestrogen therapy (ET) with gestagen every cycle for a minimum of 10, or even better, 12–14 days (evidence level II-1-3) (Grady et al.

---

*Figure 1 Description of the levels of evidence*

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>properly randomised controlled trials</td>
</tr>
<tr>
<td>II-1</td>
<td>well-designed controlled trials without randomisation</td>
</tr>
<tr>
<td>II-2</td>
<td>well-designed cohort or case-control analytic study</td>
</tr>
<tr>
<td>II-3</td>
<td>multiple time series with or without intervention (e.g. cross-sectional and uncontrolled investigational studies)</td>
</tr>
<tr>
<td>III</td>
<td>uncontrolled experiments with dramatic results</td>
</tr>
<tr>
<td></td>
<td>opinions of respected authorities that are based on clinical experience, descriptive studies and case reports; reports from expert committees</td>
</tr>
</tbody>
</table>

*According to the definition of the Preventive Services Task Force 1996, used in official statements of the North American Menopause Society (NAMS 2003).*
With long-cycle (spacing out) therapy, an increased risk cannot be excluded (Bjarnason et al. 1999), although we and others did not observe this (Rabe et al. 1997, Erkkola et al. 2002) (evidence level II-1). However, increased risk has also been demonstrated with addition of monthly sequential progestogen (SCEPT), in contrast to CCEPT (Weiderpass et al. 1999, Hill et al. 2000) (evidence level II-2). For instance, in a study by Sturdee et al. (2000), 1312 women were treated with sequential HT with at least 10 days of progestogen (evidence level II-2); there was a 6% prevalence of complex or even atypical hyperplasia. In contrast, there was no case of hyperplasia among 1196 biopsies in women treated for 9 months with CCEPT (Kliogest), and complex hyperplasia arising during previous sequential HT was converted to normal endometrium by CCEPT.

Indeed, the question of whether the risk with CCEPT is lower than with no treatment is to be investigated in further clinical trials, because, in the present studies, only a relatively small number of patients are represented. It is certain that with oestrogen monotherapy, after meta-analysis of over 30 studies (Grady et al. 1995) (evidence level II-3) a two- to fourfold risk, with long-term therapy (10 years) a 10-fold relative risk is calculated, also with lower doses (0.3 mg equine oestrogen has a five- to eightfold risk!). The elevated risk also remains for at least 5 years after stopping oestrogen therapy (Grady et al. 1995).

Oestriol can also increase the risk, presumably only with oral administration; however, this is relevant to those with repeated rather than once-daily dosing (Bertone & Weiderpass 2000) (evidence level II-2). In contrast to this, the risk is negligible with vaginal (topical) dosing of oestriol, but only in compliance with the respective specified dosages. Therefore, the usual commercial products can be used for local treatment of high-risk patients after ECa with appropriate explanation; in doing so, the use of oestriol can be recommended.

### Table 1
Risk of endometrial cancer despite combination with progestogen? Relative risk (95% confidence interval) in the studies

<table>
<thead>
<tr>
<th>First author</th>
<th>ET</th>
<th>SCEPT</th>
<th>CCEPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grady 1995</td>
<td>2.3 (2.1–2.5)</td>
<td>Cohort studies</td>
<td>–¹</td>
</tr>
<tr>
<td>Meta-analysis</td>
<td>9.5 &gt; 10 years</td>
<td>RR 0.2–0.9</td>
<td></td>
</tr>
<tr>
<td>30 trials &gt; 1970</td>
<td></td>
<td>Case control studies</td>
<td></td>
</tr>
<tr>
<td>Pike 1997</td>
<td>2.2 (1.9–2.5)</td>
<td>1.9 (1.3–2.7)</td>
<td>1.1 (0.8–1.4)</td>
</tr>
<tr>
<td>Weiderpass 1999</td>
<td>6.2 (3.1–12.6)</td>
<td>2.9 (1.8–4.6)</td>
<td>0.2 (0.1–0.8)</td>
</tr>
<tr>
<td>Persson 1999</td>
<td>4.2 (2.5–8.4)</td>
<td>1.4 (0.6–3.3)</td>
<td>–</td>
</tr>
<tr>
<td>Beresford 1997</td>
<td>4.0 (3.1–5.1)</td>
<td>1.4 (1.0–1.9)</td>
<td>1.3 (0.8–2.2)²</td>
</tr>
<tr>
<td>&gt; 5 years</td>
<td></td>
<td>3.7 (1.7–8.2)</td>
<td>2.5 (1.1–2.2)</td>
</tr>
<tr>
<td>Hill 2000</td>
<td>–</td>
<td>–</td>
<td>0.6 (0.3–1.3)</td>
</tr>
</tbody>
</table>

EPT: oestrogen progestogen therapy; CEE:—conjugated equine oestrogens; SCEPT: sequential combined EPT with ≥10 days of progestogen addition (mostly CEE 0.625–1.25 mg combined with MPA 5 mg); CCEPT: continuous combined EPT (mostly CEE 0.625 mg/MPA 2.5 mg).

¹ Persistent risk 5 years after withdrawal of HT. Missing mean values for combination with progestogens; no data with CCEPT.
² Progestogen addition during 10–21 days per month.

### HT after ECa — clinical trials

According to the latest official statements of the North American Menopause Society (2003), the treatment of moderate to severe menopause symptoms (vasomotor symptoms and sleep disruption from vasomotor symptoms) remains the primary indication for systemic ET and EPT. In women who have been treated previously for endometrial cancer, these benefits must be weighed against the risk of stimulating tumour growth and recurrence. There is no available evidence based on randomised clinical trial for an estimation. The situation is comparable to the question of applying HT after breast cancer; here too results of well-designed studies are lacking (Pritchard et al. 2002). For a definite conclusion that HT after ECa is not deleterious, a large randomised trial of 1000–2000 patients per arm would be necessary to rule out an increase of cancer recurrence of 10% or greater for HT (Chlebowski & McTiernan 1999). According to the latest ‘ACOG committee opinion’ (ACOG 2001), in the absence of HT a well-differentiated neoplasm of endometrioid cell type with superficial invasion would entail an approximate 5% risk of recurrent disease, and a moderately differentiated neoplasm with up to one-half myometrial invasion a 10–15% risk.

Indeed, so far, only five controlled studies exist to our knowledge. The essential outcomes are listed in Tables 2 and 3. All studies are retrospective, non-randomised case/control studies (evidence level II-2). These studies produced no data showing that a higher risk exists with HT after treated ECa. On the contrary, in these studies, a
tendency towards a decrease or a significant decrease in the frequency of relapses was seen, as well as longer disease-free intervals and to some extent also longer survival times.

The first study by Creasman et al. (1986) is most frequently cited. However, it is often not mentioned that 72% of 47 women with ET (conjugated equine oestrogens (CEE) 0.625–1.25 mg) were treated vaginally. Only 13 patients were treated with oral CEE, obviously without the addition of progestogens. On average, cyclical ET lasted 26 months (3–84 months), starting after surgical therapy with a mean of 15 months (0–81 months). The risk factors for ET and the control group (174 patients) were distributed equally, especially regarding prognostic factors such as tumour grade, nodal status and receptor status. The ER positive were (ET/control) 85/73% and the PR positive 78/63% (n.s.). The main results of this study were a significantly lower recurrence and mortality rate (2% vs 15%) with a longer disease-free interval \( P < 0.05 \) during ET.

In the study by Lee et al. (1990), 44 women with ECa stage I were treated exclusively with oral CEE (0.625–1.25 mg/day; cyclically) (ET), and 35% of them received sequential progestin addition (SCEPT; no details). Two-thirds of the women started HT (ET, SCEPT) in the first year, and the others later than 2 years after surgical therapy. HT lasted, on average, 64 months (2 months–11 years). During HT, no relapses or deaths were observed. In contrast, the recurrence and mortality rate was 8% in the control group of 99 patients.

In the study by Chapman et al. (1996), patients with stage II ECa were also included for the first time, showing Table 2

<table>
<thead>
<tr>
<th>First author</th>
<th>n/controls</th>
<th>ET/EPT (cases/controls)</th>
<th>Duration HT (mean)</th>
<th>Recurrences n/controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creasman 1986</td>
<td>47/174 ET:CEE</td>
<td>26 Months (3–84 months)</td>
<td>2%/15%1</td>
<td></td>
</tr>
<tr>
<td>Lee 1990</td>
<td>44/99 EPT/CEE 15/29</td>
<td>64 Months (2 months–11 years)</td>
<td>0%/8%2</td>
<td></td>
</tr>
<tr>
<td>Chapman 1996</td>
<td>62/61 CCEPT/CEE 33/29</td>
<td>39.5 Months (3–107 months)</td>
<td>3%/10%3</td>
<td></td>
</tr>
<tr>
<td>Suriano 2001</td>
<td>75/75 CCEPT/CEE 37/38</td>
<td>83/63 Months (mean)</td>
<td>1%/15%4</td>
<td></td>
</tr>
</tbody>
</table>

HT: hormone therapy=ET or EPT; ET: oestrogen-only therapy; EPT: oestrogen/progestogen therapy; SCEPT: sequential combined EPT; CCEPT: continuous combined EPT; CEE: conjugated equine oestrogen.

1 ET: CEE 0.625–1.25 mg/day vaginal (72%); CEE 0.625–1.25 mg/day oral, cyclically (15%), orally (cyclically), vaginal (topical) applications (13%).

2 No details regarding progestogen.

3 One patient with estradiol patch, one patient with vaginal CEE, 60 patients with CEE orally 0.625 mg/day; in 33 patients, combination with MPA 2.5 mg/day.

4 15% of cases and controls FIGO stage IIA, IIIA or IIIB. Progestrogen addition in 49% of the patients (80% MPA 2.5 mg/day).

Table 3

<table>
<thead>
<tr>
<th>Stage 1 (age 47–67 years)</th>
<th>n</th>
<th>10 years survival (%)</th>
<th>Years of survival</th>
<th>Years until recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCEPT Controls</td>
<td>83</td>
<td>83</td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>SCEPT after surgery</td>
<td>37</td>
<td>88</td>
<td>7.8</td>
<td>3.8</td>
</tr>
<tr>
<td>SCEPT before and after surgery</td>
<td>41</td>
<td>95</td>
<td>9.7</td>
<td>4.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage II (age 50–66 years)</th>
<th>n</th>
<th>10 years survival (%)</th>
<th>Years of survival</th>
<th>Years until recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCEPT Controls</td>
<td>71</td>
<td>70</td>
<td>6.4</td>
<td>2.4</td>
</tr>
<tr>
<td>SCEPT after surgery</td>
<td>42</td>
<td>76</td>
<td>7.6</td>
<td>3.9</td>
</tr>
<tr>
<td>SCEPT before and after surgery</td>
<td>27</td>
<td>81</td>
<td>8.8</td>
<td>4.8</td>
</tr>
</tbody>
</table>

\*Significant vs controls.

Table 3

<table>
<thead>
<tr>
<th>Stage I (age 47–67 years)</th>
<th>n</th>
<th>10 years survival (%)</th>
<th>Years of survival</th>
<th>Years until recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCEPT Controls</td>
<td>83</td>
<td>83</td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>SCEPT after surgery</td>
<td>37</td>
<td>88</td>
<td>7.8</td>
<td>3.8</td>
</tr>
<tr>
<td>SCEPT before and after surgery</td>
<td>41</td>
<td>95</td>
<td>9.7</td>
<td>4.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage II (age 50–66 years)</th>
<th>n</th>
<th>10 years survival (%)</th>
<th>Years of survival</th>
<th>Years until recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCEPT Controls</td>
<td>71</td>
<td>70</td>
<td>6.4</td>
<td>2.4</td>
</tr>
<tr>
<td>SCEPT after surgery</td>
<td>42</td>
<td>76</td>
<td>7.6</td>
<td>3.9</td>
</tr>
<tr>
<td>SCEPT before and after surgery</td>
<td>27</td>
<td>81</td>
<td>8.8</td>
<td>4.8</td>
</tr>
</tbody>
</table>

\*Significant vs controls.

SCEPT: Sequential combined oestrogen progestogen therapy.
a significantly better prognosis in the HT group in terms of staging and invasiveness of the tumours. Details on the receptor status are lacking; otherwise, the risks were distributed equally. On average, oral CEE (0.625 mg/day) was started within 8 months (0–108 months); after 5 months’ treatment, 33 of the 62 patients of the HT group (53%) received a progestin (CCEPT), 80% MPA 2.5 mg/day. The duration of HT was 39.5 months (3–107 months). There were two recurrences (3%). In the control group of 61 patients, six recurrences were observed (10%), one and four patients respectively died (two patients from ECa). These differences were not significant. Accordingly, the difference in disease-free survival failed to reach significance ($P = 0.07$), probably due to the low patient number.

In a recent study by Suriano et al. (2001), 75 out of 249 women with ECa after surgery were treated with HT and carefully matched with 75 control patients; there were no differences in age, parity, tumour stage and grading, histology, lymph node stage, surgical therapy and radiation. The ECa-risk groups were also comparable in hypertension, diabetes and obesity; data on receptor status, however, are lacking. The majority of the women had FIGO stage IB, and 15% of each group had the advanced stages IIA, IIB or IIIA. The exclusion criteria were stage IV and ECa while receiving tamoxifen.

Within 12 months, 73% of all patients started with ET (the rest within 5 years), ‘mostly’ CEE 0.625 mg/day (no details), 49% continuously combined with MPA 2.5 mg/day (CEPT?). The mean observational time was 83 months, and 63 months for the control. During HT (ET and EPT), two recurrences (1%) were observed, restricted to the pelvic area, in contrast to eight local recurrences and three cases of distant metastasis in the control group (15%). The disease-free interval was significantly prolonged in the HT group. Regarding a possible protective progestogen effect, no definite conclusion could be drawn due to the low recurrence frequency in the HT group; the same holds true for the mortality.

In addition to the four studies listed in Table 2, there is one retrospective, non-randomised case/control study (evidence level II-2) by Lauritzen (1993). In total, 147 women were treated with EPT (no details) and followed up for 10 years after ECa (Table 3). Prognosis was comparable in the groups, but data on receptor status are missing. For cancer stage I, with EPT after ECa the mean survival was 7.8 years; with EPT before and after surgery, the mean survival was 9.7 years, significantly longer than for controls (6.3 years). Similar results were observed in patients with stage II.

Finally, two observational studies without control groups (evidence level II-3) have been conducted with 31 and 20 patients respectively, which did not indicate any enhanced risk during HT (Baker 1990, Bryant 1990). Thus, according to our knowledge, we have summarised all published studies with definite examination of HT after ECa. So far, the only prospective, randomised study has been under way in the USA since 1998, as introduced in 1997 during the Annual Meeting of the American College of Obstetrics and Gynecology. In a double-blind design, CEE 0.625 mg/day (oral) is being compared with placebo. Each study arm will comprise 1000 women after ECa stages I or II and will last 3 years — in the year 2002 so far only 400 patients were recruited in each arm (AR Genazzani, personal communication). Interestingly, this important study is being conducted with ET, in contrast to all recommendations up to now and to clinical experience from the last 25 years preferring (continuous combined) EPT.

In the literature we could find only one case report published about exacerbation of ECa in patients treated with HT (evidence level II-3). During treatment with 0.625 mg equine oestrogen (without progestogen), within 1 year after surgery, abdominal metastasis developed of ER-positive, well-differentiated ECa (stage I) (Carr et al. 1996). Overall, hardly any data support the argument against administration of HT after ECa. According to the evidence of these studies (evidence level II-2, II-3), it seems likely that HT is not contraindicated in ECa stage I or II. However, selection bias may play an important role in all non-randomised studies, since the physician will prefer to offer HT to patients with better prognosis. There is a strong need for further assessment of the safety of HT after ECa by prospective, randomised trials.

**PT — an alternative strategy?**

For all forms of endometrial hyperplasia, including atypical hyperplastic adenomatosis, a therapy trial with gestagens (PT) is justified. According to observational studies (evidence level I-I-3), even higher stages of ECa can be treated with moderate to high doses of gestagen, in which case, non-aromatised gestagens, such as MPA (100–500 mg) or megestrol acetate (40–120 mg), should be used. Thus, menopausal complaints can also be alleviated or abolished.

However, gestagens in the lowest doses (5–10 mg MPA; 20–40 mg megestrol acetate) may also be considered. There is experience of their efficacy, especially with hot flushes, in patients treated for breast cancer. Thus, every PT is surely inferior to oestrogen replacement (ET or EPT), and clinical experience shows that relatively frequent treatment failures are seen. In controlled studies, however, strikingly frequent significant improvements were demonstrated with PT (Table 4), with a 60–90% reduction in hot flushes, though also with high placebo
effects (Bullock et al. 1975, Morrison et al. 1980, Schiff et al. 1980, Albrecht et al. 1981, Loprinzi et al. 1994, Quella et al. 1998, Farish et al. 2000). Based on these studies, representing results on evidence level I, corresponding trials with PT to treat climacteric symptoms are therefore also justified.

Experiences with low-dose gestagen therapy (PT) to treat hot flushes after ECa are scarce; up to now, CCEPT has been recommended and considered relatively free of risk. In our opinion, however, this must be questioned on various grounds, for certain patient groups at least.

Thus, the new discussion of gestagens in connection with the risk of breast cancer is also significant for the choice of therapy after ECa. So far, we have proceeded on the assumption that all oestrogen preparations entail an increased risk of breast cancer. In the case of a decision to treat menopausal symptoms with HT, a gestagen would mostly be combined (CEPT), or alternatively a PT, such as megestrol acetate, would be implemented (Chlebowski & McTiernan 1999, Natrajan et al. 1999, Marsden 2002, Pritchard et al. 2002, Mueck & Wallwiener 2003). However, regarding the assessment of the risk of recurrent cancer, the current data on PT compared with EPT are so limited (evidence level II-2-3) that, recently, in Germany, according to a consensus statement of the German Society of Senology, the two regimens were rated equal in entailing relapse risk after the treatment of breast cancer (Emons 2002, Mueck & Wallwiener 2003). Nevertheless, EPT is naturally much more effective than PT for the treatment of hot flushes (studies according evidence level I).

These critical judgements of gestagens are supported by the fact that in the current part of the Women’s Health Initiative study carried out only with ET (without gestagen), in women who have had a hysterectomy, no increased breast cancer risk was seen after 5 years (evidence level I). Furthermore, a series of new studies has recently been published that estimate an increased risk of breast cancer, specifically through the gestagen component of EPT, particularly with use of CCEPT (evidence level II-1-2). Altogether, the current data are certainly still very controversial; in our opinion, the gestagen effect in relation to the breast cancer risk cannot be finally commented on yet (Kenemans 2000, Marsden 2002, Seeger et al. 2003). Nevertheless, a potentially raised risk of breast cancer through the gestagen component must be included in the individual use/risk-analysis in the future. Should it be confirmed in further studies that gestagens increase the risk of breast cancer, we should not favour EPT in the future after ECa, but rather ET.

According to current studies, there are patients for whom we prefer to recommend ET without combination with gestagen, independently of the breast cancer issue: hysterectomised patients with a high cardiovascular risk should not receive a gestagen, and here a series of (above all, vascular) negative effects can be clinically very relevant. Thus, in the ‘Heart and Oestrogen/Progestin Replacement Study (HERS)’ (evidence level I), those receiving HT, in comparison to placebo, had a higher rate of reinfarction, which is associated with gestagen effects such as vasoconstriction or mobilisation of atherosclerotic plaques. In our opinion, this is also valid for the Women’s Health Initiative (evidence level I) — here, likewise, a group with higher cardiovascular risks was treated that certainly for the most part had atherosclerotic vessel changes (age over 60 years, 66%; smokers, 50%; hypertension, 36%; BMI > 30 kg/m, 34%).

It is well known from epidemiological studies, just as from experimental studies (evidence level I), that, in contrast to women with preexisting atherosclerosis, for cardiovascular healthy women no gestagen-dependent risk has to be considered (Mikkola & Clarkson 2002). For example, in double-blind, placebo-controlled trials, we could prove that the vessels in healthy women react immediately and adequately to a vasoconstrictive stimulus through reactive dilatation, while in women after infarction, the endothelial reserve is drastically reduced (Mueck et al. 1999). For this reason, our current recommendation of ET, instead of EPT, to treat menopausal symptoms after ECa applies primarily to women with cardiovascular

<table>
<thead>
<tr>
<th>First author</th>
<th>n</th>
<th>Progestogen</th>
<th>Reduction of the frequency of hot flushes (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullock 1975</td>
<td>57</td>
<td>MPA</td>
<td>90 (%)</td>
</tr>
<tr>
<td>Morrison 1980</td>
<td>34</td>
<td>MPA</td>
<td>68 (%)</td>
</tr>
<tr>
<td>Albrecht 1981</td>
<td>6</td>
<td>MPA</td>
<td>87 (%)</td>
</tr>
<tr>
<td>Schiff 1980</td>
<td>32</td>
<td>MPA</td>
<td>74 (%)</td>
</tr>
<tr>
<td>Loprinzi 1994</td>
<td>80</td>
<td>MA</td>
<td>85 (%)</td>
</tr>
<tr>
<td>Quella 1998</td>
<td>58</td>
<td>MA</td>
<td>89 (%)</td>
</tr>
</tbody>
</table>

MPA: medroxyprogesterone acetate; MA: megestrol acetate.
disease. This is, however, of great practical relevance, counting hypertension, diabetes mellitus, metabolic syndrome, polycystic ovary syndrome and obesity as the most important risk factors for ECa that simultaneously produce an increased cardiovascular risk! Thus, the options for PT as an alternative to HT will be considerably reduced.

Raloxifene or tibolone — after ECa?
The treatment of ECa usually includes ovariectomy, which increases the risk of coronary heart disease (CAD) and osteoporosis. For prevention and therapy of CAD, statins are the first choice (Hillard 2000); for osteoporosis, bisphosphonates, as well as raloxifene, can be considered (evidence level I). So far, no data are known to us that could prohibit the use of raloxifene after ECa. In contrast to tamoxifen, raloxifene does not have a proliferative effect on endometrium (Hillard 2000) (evidence level I), and, as far as we know, there are no reports of increased risk of ECa under raloxifene treatment. Nevertheless, ECa is listed in the data sheet for raloxifene as an absolute contraindication to treatment, ‘as safety in this patient group has not been adequately studied’. This may be based on the fact that, up to now, only small numbers of cases are available from studies with endometrial biopsies before and after therapy.

Likewise tibolone, according to the existing studies (evidence level I, II-I), has no proliferative effect on the endometrium (Kloosterboer & Sands 2000). However, like breast cancer, ECa is listed as a contraindication in the data sheet for tibolone. In comparison to raloxifene, tibolone offers the advantage of effectively treating both menopausal and urogenital oestrogen deficiency complaints. With the use of tibolone after ECa, however, the same legal, realisable patient information as with HT must be given i.e. informed consent regarding “off label” use after ECa, especially because, in comparison to HT, hardly any clinical data on these risks exist for tibolone. However, because the experimental studies are promising, it is justifiable to consider tibolone as an alternative.

Management of hot flushes — nonhormonal alternatives
From a legal point of view, it appears wise to consider alternatives which do not have hormone-dependent neoplasias listed as contraindications. The German Society of Senology recently recommended treatment with selective serotonin-reuptake inhibitors (SSRIs), such as venlafaxine or fluoxetine, after breast cancer (Emons 2002, Mueck & Wallwiener 2003). In fact, it has been proved through randomised, placebo-controlled trials that there is a positive efficacy against hot flushes (evidence level I). The tricyclic antidepressant oppiranol is also effective; it has been used in Germany for years to treat menopausal complaints, and is particularly well tolerated (Mueck & Stoll 2001). The antiepileptic gabapentin has also been shown to reduce hot flushes; this was only recently demonstrated in the first double-blind, placebo-controlled trial (Guttuso et al. 2003).

Other non-hormonal alternatives are methylodopa, clonidine, veraplipride (an antidopaminergic), lipophilic beta-blockers such as propranolol, tranquilisers or related substances (such as belladonna and ginseng), and vitamin E (Albertazzi 2002). Only a few studies on these substances (evidence levels I and II-1-3) have shown an efficacy strikingly better than in clinical practice. Therefore, we do not recommend these substances as alternatives to HT.

Currently, the most effective alternatives seem to be the SSRIs. They can, however, have side effects such as nausea, constipation, dry mouth, central nervous system effects, and — as recently reported — gastrointestinal bleeding. Besides this, there have been reports of an increased risk of suicide, because the elimination rate can be too fast in some patients, leading to acute withdrawal symptoms. After breast cancer, SSRIs may be prescribed instead of HT, but this is based on another risk/benefit situation (Chlebowski & McTernan 1999, Pritchard et al. 2002, Mueck & Wallwiener 2003). However, at present, for use after ECa, we would favour SSRIs over HT only when the patient refuses HT after informed consent, because its safety profile is, in our opinion, not as favourable.

Certainly, the use of various herbal compounds, such as phytoestrogens and dietary supplements, is of growing significance, although the risk of endometrial hyperplasia or ECa cannot be excluded (Johnson et al. 2001) (evidence level II-3). Therefore, hormone-dependent neoplasias are listed as contraindications for many of these products. The compositions of the phytopreparations, such as those from soya, isoflavonoids, red clover, Cimifuga extract, agnus castus and St John’s wort, are indeed complex, variable and only partly known. The actions of the active ingredient have also been little investigated; for example, the recent verification of the first clinically very relevant interactions with St John’s wort. Generally, the actions, such as side effects, are hard to determine. Accordingly, the study outcomes are also controversial; therefore, a variety of studies (evidence level I) have been published.

In analyses and relevant consensus statements on the basis of over 1000 publications (evidence levels I and II), the possibility of replacing HT with phytopreparations is assessed in a more reserved manner (North American Menopause Society 2000, Glazier & Bowman 2001).
treatment trial — before use of HT — is nevertheless worthwhile. Phytopreparations are socially well accepted, and, with longer treatment, satisfactory effects can be attained in some women, because of the high compliance of women in therapy with plant-based preparations (‘natural products’).

Conclusion and practical recommendations

HT can be given after treatment of ECa stage I or II — this is undoubtedly the most effective and the only causal treatment of menopausal estrogen deficiency symptoms. However, there is a strong need to determine the safety of HT after ECa in prospective, randomised trials, which have yet to be done. Up to now, only non-randomised case/control studies and uncontrolled investigational studies have been available; that is, the recommendations are based on studies with evidence levels II-2, II-3 and III. Therefore, it is appropriate that ECa is listed as a contraindication in all data sheets, and patients must be informed of this. This also applies to tibolone and raloxifene and a large number of the phytopreparations. Gestagens have been proposed for high-dose treatment of disseminated ECa and also in lower doses for the management of hot flushes. Furthermore, relatively efficacious alternatives are particular psychotherapeutic drugs. Urogenital complaints (such as atrophic vaginitis) can be treated with bioadhesive vaginal moisturisers (Replens) or with vaginal oestriol and oestradiol preparations; in doing so, the prescribed dose must be adhered to.

For relief of hot flushes, on the basis of the reviewed studies (evidence levels have been mentioned), we recommend the following steps:

1. General measures such as reduction of caffeine and nicotine consumption, suitable clothing, avoidance of warmth, exercise in the fresh air, breathing and relaxation exercises, and a balanced diet.
2. Treatment trial with phytopreparations without ECa as a contraindication (however frequent disappointing effects).
3. Treatment trial with gestagens, preferably MPA or megestrol acetate.
4. Low-dose ET, for example with oestradiol patches or gel; CCEPT only in cardiovascually healthy patients (note risk factors for ECa such as hypertension, diabetes, obesity, metabolic syndrome and PCO syndrome!)
5. On the refusal of hormonal treatment by the patient: opipramol or an SSRI such as venlafaxine.

Should it be found in further clinical trials that the risk of breast cancer is increased with gestagens, we will use ET instead of the previous CCEPT for our choice of HT in our clinical practice.

In the absence of well-designed studies, the choice of HT after ECa should be based on prognostic indicators, including depth of invasion, degree of differentiation, and cell type. These predictors can assist the physician to estimate the risk of recurrent tumours and can assist the patient to determine the degree of risk she is willing to assume on an individualised basis, and to compare potential benefits and risks.

References


Creasman WT 1999 HRT and women who have had breast or endometrial cancer. *Journal of Epidemiology and Biostatistics* **4** 217–225.


Emons G & Mustonen M 2002 No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years. *Journal of the British Menopause Society* **8** 155–156.


